The insider sales are small in dollar terms and follow a routine earnings cycle. No bearish signal — treat as noise. Monitor the next 10-Q for any change in operating momentum, particularly Consumables and Infusion Systems revenue trends.
Price Chart
Executive Summary
A cluster of insider trades at ICU Medical includes a $304K open-market sale by the VP and General Counsel and a $298K sale by a director, both occurring within a week of the Q1 2026 earnings release. The earnings showed GAAP revenue down 12% YoY due to the IV Solutions divestiture, though non-GAAP organic revenue grew 1% and adjusted EPS rose to $1.97 from $1.72. The sales are modest relative to the $3.1B market cap (0.02%) and are likely routine portfolio adjustments rather than a bearish signal.
Key Financial Metrics
Key Facts
- VP and General Counsel sold 2,447 shares at $124.08 for $303,624 on May 14, 2026.
- Director Greenberg sold 2,424 shares at $122.91 for $297,936 on May 12, 2026.
- Total open-market sales of ~$602K represent ~0.02% of ICUI's $3.1B market cap.
- Q1 2026 GAAP revenue declined 12% YoY to $530.2M due to IV Solutions divestiture; non-GAAP organic revenue grew 1%.
- Adjusted diluted EPS was $1.97 vs $1.72 in Q1 2025; GAAP net income was $30.1M vs a loss of $15.5M a year ago.
- Multiple directors exercised derivative securities and received grants on May 13, 2026 — all non-cash transactions with no economic value.
- Earnings were filed 8 days before the cluster, and the CEO described results as 'generally in line with our expectations.'
Financial Impact
Total insider sales of ~$602K, or 0.02% of market cap — immaterial relative to company size.
Risk Factors
- GAAP revenue decline of 12% YoY, though structurally driven by the IV Solutions divestiture.
- Adjusted EBITDA was essentially flat YoY at $98.7M vs $99.4M, suggesting limited operating leverage.
- Historical calibration shows prior neutral reports on ICUI had negative T+20 returns, but this filing lacks material directional content.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ICUI-1778862025520 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 28d ago | Insider Cluster | $167.58 $157.60 | ▼ −5.96% | ▼ −4.75% | $160.05 (−4.49%) |
Aug 13, 2026 7w ago | Insider Cluster | $182.98 $182.84 | ▲ +0.08% | ▼ −1.29% | $160.05 (+12.53%) |
Aug 12, 2026 7w ago | Insider Cluster | $179.34 $187.26 | ▲ +4.42% | ▲ +4.86% | $160.05 (−10.75%) |
Aug 11, 2026 7w ago | Insider Cluster | $179.34 $187.26 | ▲ +4.42% | ▲ +4.86% | $160.05 (−10.75%) |
May 15, 2026 20w ago | Insider Cluster | $118.72 $133.31 | ▲ +12.29% | ▲ +11.33% | $160.05 (+34.82%) |
Apr 23, 2026 23w ago | Press Release | $124.55 $115.45 | ▼ −7.31% | ▼ −8.78% | $160.05 (+28.51%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access